Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers

NCT ID: NCT00770939

Last Updated: 2011-10-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-07-31
• Study Completion Date: 2010-08-31

Brief Summary

Diabetic foot ulcers are a challenge to health care professionals because there are only few effective topical therapeutic interventions.

Growth factor treatment has shown to be beneficial for healing of diabetic foot ulcers in conjunction with extensive surgical debridement. Autologues platelet releasate which contains platelet derived growth factor appears to be more effective than standard therapy in case studies.

This protocol will evaluate the healing effect of Vivostat PRF treatment of non-eschemic foot ulcers to identify responders and to enable sample size calculation for a subsequent pivotal trial.

Conditions

Diabetic Foot Ulcers

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Vivostat PRF

Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• At least 4 weeks history (with wound area measurements) within a wound care institution before the first visit (week -3). In case of referral the patient history must be documented
• All patients must complete a 3 week screening period i.e. they will be interviewed and accessed at the first meeting. During the 3 week period patient compliance will be monitored.
• Age >18 years
• Type I or Type II Diabetes Mellitus
• Ulcer at or below the ankle which has been present for at least 4 weeks, and has received best practice care
• Ulcer area between 0,5 and 16 cm2
• If there is more than one ulcer or bilateral ulcers, the investigator shall choose the one index ulcer to be treated (typically the largest one). The other ulcers will receive standard care and is not included in the study
• Ulcer type: University of Texas grade IA.
• Evidence of adequate arterial perfusion: Toe pressure reading of ≥ 30 mmHg or if toe is missing, transcutaneous oxygen (TcPO2) of ≥ 30mmHg on the foot.
• Patient foot is appropriately off loaded (contact cast, pneumatic walking cast)
• Orthopaedic assessment has been completed to rule out a mechanical source of ulceration
• Relative wound area reduction less than 50% from week -3 to week 0 (pre-screening period)
• Signed informed consent

Exclusion Criteria

• Clear indication for surgery (vascular reconstruction or skin transplant)
• Ulcer with exposed bone or tendon
• Bone involvement (probe to bone or x-ray)
• Patients with 3 ulcers or more at the foot investigated
• Osteomyelitis
• Clinical signs of infections
• Necrosis in the wound (one week into the screening period).
• Patients with known MRSA
• Malnutrition. Albumin < 2,5g/dl
• Ulcers resulting from electrical, chemical, radiation burns
• HbA1c > 12%
• Male: Hb < 8 mmol/l (12,9 g/dlFemale: Hb < 7 mmol/l (11,3 g/dl)
• Platelet count <140 *109/l
• Pregnancy and fertile women not practicing sufficient birth control
• Fertile women having a positive pregnancy test week 0 Lactating women
• Patients on haemodialysis
• History of peripheral vascular repair within 4 weeks prior to study enrollment
• Bleeding disorders, haemophilia, sickle cell disease, thrombocytopenia, and leukaemia or blood dyscrasias
• Current treatment for malignancy or neoplastic disease or collagen vascular disease
• Highly communicable disease or diseases that may limit follow - up (e.g. immunocompromised conditions, hepatitis, active tuberculosis)
• Patient has inadequate venous access to draw blood
• History of alcohol or drug abuse within the last year prior to randomization
• Patient known to have psychological, developmental, physical, emotional or social dis-order or other ailments that may interfere with the study requirements
• Patients enrolled in an other clinical trial for wound treatment within 30 days prior to enrollment
• Non-compliance in the screening period
• Patients who have received growth factor therapy e.g. becaplermin within 7 days prior to enrollment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vivostat

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Ruge

Role: STUDY_DIRECTOR

Vivostat

Locations

Woundhealing Centre Bispebjerg Hospital

Copenhagen, , Denmark

Diabetes Klinik Bad Mergentheim GmbH

Bad Mergentheim, , Germany

Gesundheitszentrum Mathias Hospital

Rheine, , Germany

Krankenhaus der Barmherzigen Brüder

Trier, , Germany

Diabetes/ Endokrin sektion

Lund, , Sweden

Countries

Denmark; Germany; Sweden

Other Identifiers

2007-001

Identifier Type: -

Identifier Source: org_study_id